Elevation Oncology’s EO-3021 shows ‘promising’ Phase 1 anti-tumor results

Elevation Oncology announced “promising” initial data from the dose escalation portion of the ongoing Phase 1 clinical trial of EO-3021 in patients with advanced, unresectable or metastatic solid tumors likely to express Claudin 18.2, including gastric, gastroesophageal junction or GEJ, pancreatic or esophageal cancers. The company expects to advance into monotherapy dose expansion and initiate combination cohorts in the months ahead, as well as reporting additional data from the ongoing trial in the first half of 2025. EO-3021 was observed to be generally well-tolerated. No Grade 4 or 5 treatment-related adverse events were reported, and less than 10% of patients discontinued EO-3021 due to adverse events. In seven patients with Claudin 18.2 in greater than or equal to20% of tumor cells at IHC 2+/3+, the objective response rate was 42.8% and the disease control rate was 71.4%, including two patients with stable disease. Elevation Oncology plans to initiate enrollment in the dose expansion portion of the ongoing Phase 1 clinical trial, further exploring two doses of EO-3021. Elevation Oncology expects to share additional data from the Phase 1 trial, including from the dose expansion cohort, in the first half of 2025. Elevation Oncology expects to initiate dosing in the combination portion of the Phase 1 trial by year-end 2024.